AstraZeneca snagged $250 million-plus for its cancer drug Zoladex in the U.S., where it brought in only $69 million last year. The deal, AZ's latest slim-…

Stada said it has a third suitor in the mix to buy the company, and Bernstein analyst Ronny Gal thinks he may know who it is.

The impending approval of Momenta's copy of Teva’s long-acting version of blockbuster Copaxone is now expected to be delayed.

Roche’s Genentech has sued Amgen for not giving up the info Genentech experts need to mount a patent infringement attack on Amgen’s biosimilar for Avastin, its…

PRA and Takeda are building a Japan JV, Sun's quarterly profits dropped, ASLAN posted positive top-line phase 2 data for varlitinib.

​​​​​​​Ex-Turing Pharma CEO Martin Shkreli can’t get away from his bad rep.

Pharma watchdog Elijah Cummings blasted Trump on Thursday for what he said was a made-up story.

Stada already had two interested buyers in the mix as of earlier this week. And now, it’s got three.

President Trump told Robert Kennedy Jr. he won't "back down" from plans to create vax safety commission, despite guaranteed "uproar"…